Stem cells created from cells taken from juvenile Huntington’s disease (JHD) patients showed a delay in developing into mature neurons, but one that is reversible, a study reports. The study, “Characterization of Neurodevelopmental Abnormalities in iPSC-Derived Striatal…
There may be no cure yet for Huntington’s disease, but patients — and their families — can still do plenty to extend their life expectancy through proper diet, exercise, and emotional support. That’s the message Norway’s Astri Arnesen wants to share with the world. Arnesen, president of the European…
Roche will now be responsible for the development and marketing of Ionis Pharmaceuticals’ IONIS-HTTRx after exercising its option to license the investigational drug, designed to treat Huntington’s disease (HD). This move follows highly promising results from a Phase 1/2a clinical trial. The randomized, double-blind, placebo-controlled trial (NCT02519036) tested…
Beneficial effects of the investigational neuroprotective drug olesoxime have mainly been attributed to its effects on mitochondria, but new research suggests it also blocks calpain — a molecule directly involved in Huntington’s disease. The findings indicate that exploring the drug’s exact mechanism might bring scientists closer to effective treatments for Huntington’s.
Get regular updates to your inbox.